- December 3, 2018 17:34 (CET)
Cyxone (publ) announced today that the internationally renowned research company First Berlin Equity Research has published an updated independent analysis report of Cyxone.
- November 28, 2018 08:47 (CET)Regulatory
Cyxone (publ) announced today that the preclinical program for drug candidate T20K in multiple sclerosis (MS) has been concluded following positive results in the toxicology studies. The drug candidate T20K has now shown to be safe for people to ingest and the next step is to test the effect of T20K in clinical trials.
- November 21, 2018 08:46 (CET)Regulatory
Summary of the interim report
- October 31, 2018 08:25 (CET)
Cyxone (publ) announced today that the internationally renowned research house First Berlin Equity Research has published an independent analysis report of the company.
- October 23, 2018 08:25 (CEST)Regulatory
Cyxone AB (publ) announced today that the company has selected the clinical site that will carry out the drug candidate T20K's first in man study. The clinical site located in Western Europe has been carefully evaluated based on a number of crucial criteria and will treat the first healthy volunteers in the T20K clinical phase 1 study developed for the treatment of multiple sclerosis (MS). This means that the company is well aligned with the planned preparations for T20K's first clinical study prior to the start of recruitment of healthy volunteers as well as completion of the remaining preclinical program.
- August 17, 2018 14:23 (CEST)Regulatory
Cyxone AB (publ) announced today that the company changes Certified Adviser.
- August 17, 2018 08:00 (CEST)Regulatory
Summary of interim report
- August 15, 2018 10:00 (CEST)Regulatory
Cyxone AB (publ) announced today that the company has decided to bring forward the publication of the interim report for the period January-June 2018.
- July 10, 2018 10:31 (CEST)Regulatory
Cyxone AB (publ) announced today that the company’s second and last phase of the pilot study in inflammatory bowel disease (IBD) with its cyclotide technology has been concluded. The results add to the growing body of evidence around the cyclotide technology, deepening the understanding of this natural plant protein.
- June 29, 2018 14:25 (CEST)
Cyxone AB (publ) announced today that the company has appointed Mangold Fondkommission to provide market making services for the company’s share. The purpose of the market maker is to improve the liquidity of the share and reduce the difference between the buying and selling price. The assignment commences on July 2, 2018.